871026-10-7

Basic information

• Product Name: 5H-Pyrrolo[3,2-d]pyrimidine-5-ethanol, 4-chloro-, benzoate (ester)
• CAS NO: 871026-10-7
• Molecular Formula: C15H12ClN3O2
• Molecular Weight: 301.732
• Mol File: 871026-10-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5H-Pyrrolo[3,2-d]pyrimidine-5-ethanol, 4-chloro-, benzoate (ester)(CAS DataBase Reference)
• NIST Chemistry Reference: 5H-Pyrrolo[3,2-d]pyrimidine-5-ethanol, 4-chloro-, benzoate (ester)(871026-10-7)
• EPA Substance Registry System: 5H-Pyrrolo[3,2-d]pyrimidine-5-ethanol, 4-chloro-, benzoate (ester)(871026-10-7)

Safety Data

• Hazardous Substances Data: 871026-10-7(Hazardous Substances Data)

Upstream product

• 84905-80-6 4-Chloro-5H-pyrrolo[3,2-d]pyrimidine 
• 939-54-8 2-bromoethyl benzoate 
• 39252-69-2 2-iodoethyl benzoate 

Downstream Products

• 919278-18-5 2-[4-(4-amino-3-chlorophenoxy)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl benzoate 
• 1346176-19-9 2-[4-({3-chloro-4-[3-(trifluoromethoxy)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethanol 
• 871026-95-8 2-(4-{[3-chloro-4-(3-chlorophenoxy)phenyl]amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethanol 
• 1033809-21-0 C₂₉H₂₂ClN₅O₄ 
• 1033809-54-9 C₂₉H₂₂ClN₅O₄ 
• 1033809-01-6 C₂₈H₂₂ClN₇O₃ 
• 1033810-59-1 C₂₈H₂₁ClN₆O₃ 
• 1033810-53-5 C₃₁H₂₄ClF₃N₄O₄ 
• 1033810-50-2 C₂₉H₂₂ClN₅O₃ 
• 1033810-47-7 C₃₀H₂₅ClN₆O₃ 
• 1033810-39-7 C₂₉H₂₁ClN₄O₄ 
• 1033810-34-2 C₃₀H₂₃ClN₄O₄ 

Relevant articles and documents

Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold

Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer. To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivatives capable of fitting into the receptors' ATP binding site. Among the prepared compounds, 34e showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity. The X-ray cocrystal structures of 34e with both HER2 and EGFR demonstrated that 34e interacts with the expected residues in their respective ATP pockets. Furthermore, reflecting its good oral bioavailability, 34e exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models. On the basis of these findings, we report 34e (TAK-285) as a promising candidate for clinical development as a novel HER2/EGFR dual kinase inhibitor.

FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF

-